SecBot SecBot
Biotech Drug Report Generated Aug 21, 2026

Rhapsido

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3 / approved-stage (FDA catalyst record 2025-09-30; EU opinion Feb 2026)
Time to market
US: already at commercial/approved stage per the FDA catalyst record (2025-09-30). EU: authorisation decision pending after the Feb 2026 opinion. CINDU label expansion still in Phase 3 (study estimated to complete ~2029).
Why 3/10
No hard, dated binary is confirmed in the next ~12 months: the US FDA approval catalyst (2025-09-30) and the EMA opinion (2026-02-27) have already passed, and the Phase 3 CINDU readout (est. primary completion 2026-05-22) has no confirmed results date in the data, so this approved, commercial-stage drug, a small part of a mega-cap pipeline, scores in the 3-5 band.
Actionable Insight NEUTRAL

The next potential re-rating events are the CINDU Phase 3 topline (est. primary completion was 2026-05-22; no results posted yet in the data) and the EU authorisation decision that normally follows a CHMP opinion, but neither is a dated binary in hand, so there is no scheduled single-day catalyst to trade. Given Rhapsido's small weight inside Novartis, treat it as pipeline news flow rather than a standalone stock thesis, and re-verify approval/sales claims with external sources once web search is available.

Price Chart

Loading chart...

Executive Summary

Rhapsido is the brand name for remibrutinib, a Novartis immunology drug (development code LOU064). SecBot's ingested FDA/EMA/trial records show: a Type 1 new-molecular-entity NDA (218436) recorded as an approval catalyst on 2025-09-30 with a positive ~6% NVS price reaction; an EMA European public assessment report ("Status: Opinion") dated 2026-02-27; a Phase 3 trial in chronic inducible urticaria (est. primary completion 2026-05-22); and a completed Phase 2 peanut-allergy study.

How It Works

An oral small-molecule immunology drug (a new molecular entity per its FDA filing) that dampens a key immune-cell signaling enzyme involved in allergic/hive-type responses, commonly described as a BTK inhibitor, developed as a pill for chronic hives (urticaria) not controlled by antihistamines, rather than an injectable biologic. Note: the mechanism label comes from general drug-class knowledge; the tool results received this session identify the molecule and indications but not the mechanism explicitly.

Trial Status

FDA/OPENFDA records show a Type 1 new-molecular-entity filing (NDA 218436) for remibrutinib dated 2025-09-30, classified by the ingestion pipeline as an approval catalyst; NVS rose about +6.1% (1-day) and +6.7% (5-day) around that date. An EMA EPAR entry for Rhapsido/remibrutinib shows "Status: Opinion" as of 2026-02-27. A Phase 3 trial (NCT05976243, ~362 patients) in chronic inducible urticaria (CINDU) inadequately controlled by H1-antihistamines is active but not recruiting, with estimated primary completion 2026-05-22 and no results posted yet; a Phase 2 peanut-allergy study (NCT05432388) is completed.

The Two-Sided Case

▲ Bull Case4
FDA/OPENFDA records show NDA 218436 for remibrutinib classified as a 'fda_approval' catalyst (Type 1 new molecular entity) dated 2025-09-30 with high confidence, indicating US regulatory success and launch.
NVS shares rose +6.14% over 1 day and +6.68% over 5 days around that catalyst date (price ~120.43 before, ~127.83 after), consistent with a positive regulatory event.
European momentum: an EMA EPAR entry for 'Rhapsido, remibrutinib' shows Status: Opinion as of 2026-02-27, the step toward EU authorisation.
Franchise expansion: a Phase 3 trial (NCT05976243, ~362 patients) in chronic inducible urticaria not controlled by antihistamines is under way (est. primary completion 2026-05-22), and a Phase 2 peanut-allergy study (NCT05432388) is completed, multiple shots on goal beyond the initial indication.
▼ Bear Case4
External web verification was impossible this session, so actual approval status, prescription/sales ramp, and competition could not be confirmed, the catalyst outcome field is null and must not be read as an authoritative approval.
No confirmed hard, dated catalyst in the next ~12 months: the US decision date (2025-09-30) and EMA opinion (2026-02-27) are behind us, and the CINDU Phase 3 readout has no confirmed results/report date in the data.
Concentration is tiny: Rhapsido is one asset inside a mega-cap; even a large urticaria franchise is a small slice of Novartis's valuation, limiting single-drug share-price impact.
Broader positioning is mixed-to-cautious: 2026-Q2 13F data shows several tracked managers trimming or exiting NVS (Goldman Sachs -54.3%, Dodge & Cox near-exit -89.1%, UBS -33.9%, BMO -59.5%), and the analyst snapshot is 'hold' (10 buy / 14 hold / 4 sell / 6 strong buy) with implied upside of roughly 2.5%.

Upcoming Catalysts

  • CINDU Phase 3 (NCT05976243) topline results, est. primary completion 2026-05-22, no results posted in the data as of the 2026-03-03 refresh
  • EU (EMA/EC) authorisation decision following the 2026-02-27 'Status: Opinion' EPAR
  • Potential label-expansion data from the completed Phase 2 peanut-allergy study (NCT05432388)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov